Cancer’s Hidden Bill: New Study Maps Who Pays the Price

When a person receives a cancer diagnosis, the first questions are usually about survival, treatment options, and prognosis. But for a growing number of patients, another question quietly takes center stage: how will I pay for all of this? Researchers call this phenomenon financial toxicity, a term that captures the direct and indirect economic consequences of cancer care, from out-of-pocket treatment expenses to lost income, travel costs, childcare, and meals while attending appointments. Now, one of the largest real-world studies of its kind has mapped exactly who bears this burden and how it connects to other measures of suffering, in findings that could reshape how cancer centers screen and support their patients.

The new research, published in the journal Supportive Care in Cancer, comes from the Cleveland Clinic Cancer Institute, a large tertiary care center in Ohio that has operated a financial navigation program since 2021. Led by Mahir Khan and Betty K. Hamilton, the team analyzed data from 1,906 patients with any cancer diagnosis who completed a validated financial toxicity questionnaire between June 2021 and February 2024. The instrument they used, known as COST-FACIT, is an eleven-item patient-reported survey that produces a score from 0 to 44, with lower scores indicating greater financial harm. Because the tool has been previously validated against quality-of-life impacts, the researchers could grade each patient’s financial toxicity from no impact to high impact, creating a standardized way to measure something that has long been discussed anecdotally but rarely quantified at scale.

The results reveal a striking picture of economic strain woven through the cancer population. Of the 1,906 patients, 43 percent reported no financial toxicity at the time of initial treatment, while 33 percent reported mild impact, 22 percent reported moderate impact, and 2 percent reported high impact. In other words, more than half of the patients screened showed at least some measurable financial harm from their diagnosis and care. The most common malignancies in the cohort were gastrointestinal cancers, breast cancer, lymphoma, lung cancer, and myeloma, and the median age was 65 years. The majority of patients were non-Hispanic White, over half were married, and nearly half had private insurance, reflecting the demographics of the region the center serves.

But the study’s most technically significant contribution lies in its identification of risk factors. Using ordinal cumulative logistic regression, a statistical approach that models the odds of belonging to a higher financial toxicity category, the researchers found that younger age, female sex, Black race, Hispanic ethnicity, single marital status, Medicaid insurance, smoking history, and higher neighborhood deprivation were all associated with greater financial harm. In multivariable analysis, these associations held firm: non-Hispanic Black patients had 62 percent higher odds of higher financial toxicity compared to non-Hispanic White patients, Hispanic patients had double the odds, Medicaid recipients had 2.35 times the odds compared to those with private insurance, and former or current smokers had roughly 34 to 41 percent higher odds. Each five-percentile increase in the Area Deprivation Index, a validated measure of neighborhood disadvantage that accounts for income, education, employment, and housing quality, raised the odds of higher financial toxicity by 4 percent.

The researchers also connected financial toxicity to other patient-reported outcomes collected routinely at the cancer center, including the PROMIS-10 global health survey, the National Comprehensive Cancer Network Distress Thermometer, and the PHQ-9 depression screener. Higher distress, more severe depression symptoms, and lower physical and mental health scores were all strongly associated with greater financial harm. This finding is consistent with a growing body of literature suggesting that financial strain and psychological suffering are deeply intertwined, each potentially amplifying the other in a vicious cycle that erodes quality of life during an already difficult period.

Perhaps the most surprising result, however, is what the study did not find. Despite prior research linking financial insolvency to early mortality among cancer patients, the Cleveland Clinic team found no significant association between financial toxicity categories and overall survival or time to first treatment in the entire cohort. The Area Deprivation Index, by contrast, was associated with longer time to first treatment, with patients in more disadvantaged neighborhoods waiting roughly 2 percent longer to begin care. This small but measurable disparity suggests that neighborhood-level disadvantage may create barriers to timely care even when individual patients report similar levels of financial strain, highlighting the difference between community-level deprivation and patient-perceived economic burden.

Yet the story took an unexpected turn when the researchers performed a sensitivity analysis. When they measured survival from the time of COST-FACIT completion rather than from diagnosis, moderate or high financial toxicity was associated with worse overall survival, with a hazard ratio of 1.44. This association was particularly pronounced among patients with hematologic malignancies such as leukemia, lymphoma, and myeloma, where the hazard ratio reached 2.39. The researchers caution that this finding is exploratory and may be influenced by guarantee-time bias, a statistical artifact that arises when survival is measured only from the point at which a patient has survived long enough to complete a survey. Still, the signal among blood cancer patients is intriguing, especially since these patients are often diagnosed and begin treatment in the inpatient setting, potentially missing the initial financial navigation touchpoint available to solid tumor patients.

The study also highlights the practical challenges of implementing financial toxicity screening at scale. Of the 16,814 unique patients seen at the cancer center during the study period, only 1,906 completed a COST-FACIT assessment, and sensitivity analyses revealed that these patients differed systematically from those who did not. Patients who completed the survey were younger, had lower body mass index, were more likely to be non-Hispanic White, and were more likely to have Medicare insurance. They also reported higher distress scores and were more likely to complete other patient-reported outcome measures. The researchers note that many patients are reluctant to share financial information, and that capacity constraints across multiple sites may have prevented some patients from receiving a survey at all. These differences introduce potential bias and limit the generalizability of the findings to the broader cancer population.

The financial navigation program itself represents a promising intervention model. When patients are scheduled for treatment, financial navigators review their insurance benefits, including deductibles and maximum out-of-pocket expenses, and inform patients of their individualized costs for each treatment. They evaluate grant opportunities, medication assistance programs, and eligibility criteria based on diagnosis and prescribed drugs, and discuss barriers to care. While the goal is to offer the COST-FACIT every six months, longitudinal data remains incomplete, and the researchers are working to optimize collection to determine how financial toxicity changes over time and whether navigation resources actually reduce it.

As cancer treatment costs continue to rise with the rapid advancement of novel diagnostics and therapeutics, the burden of financial toxicity will only grow. This study provides one of the most detailed real-world portraits of who bears that burden, confirming that younger patients, racial and ethnic minorities, those with public insurance, smokers, and residents of disadvantaged neighborhoods face the greatest economic harm. It also demonstrates that financial strain is inseparable from psychological distress and diminished quality of life. While the relationship between financial toxicity and survival remains uncertain and requires further study within specific disease groups, the message for cancer centers is clear: screening for financial harm should be as routine as screening for depression or distress, and interventions to reduce it deserve the same rigor as any other supportive care measure.

Subject of Research: Assessing financial toxicity with COST-FACIT: experience from a tertiary care cancer center

Article Title: Assessing financial toxicity with COST-FACIT: experience from a tertiary care cancer center

Article References: Khan, M., Dewey, E. N., Strzalka, C., Bhan, A., Hurwitz, H. M., Stegh, H., Hurn, R., Tomer, J., Patil, S., Bell, K., & Hamilton, B. K. (2026). Assessing financial toxicity with COST-FACIT: experience from a tertiary care cancer center. Supportive Care in Cancer, 34(11), Article 1119. https://doi.org/10.1007/s00520-026-11344-z

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11344-z

Keywords: Assessing, financial, toxicity, COST-FACIT, experience, tertiary, care, cancer, center, scientific research